Pterostilbene · Safety Data · Evidence Explained

Reading time: 8 minutes · Nutriop Longevity

Chapter 1

Two Results in One Table

Most supplement studies reach you as a single sentence: this compound did that. The trial at the centre of this article reaches you as a table, and two of its lines point in opposite directions.

In 2014, a research team published a randomised, double-blind, placebo-controlled trial of pterostilbene, a close chemical relative of resveratrol. One line in their results was good news: in the people taking the higher dose, blood pressure came down.

The other line was the kind of result that anyone selling a compound would rather not see. In the people taking pterostilbene on its own, LDL cholesterol went up.

The researchers published both. They also reported a third result that turned out to be the most useful of all. In the group that took pterostilbene together with a grape extract, the LDL rise did not show up.

By the end of this article you will know what that trial measured, why its awkward result makes its good result more believable, how pterostilbene differs from resveratrol, and what the grape-extract group can and cannot tell you. You will also know what we think a sensible person who takes pterostilbene, or is thinking about it, should do with all of this.

Section 1

A Trial That Measured More Than It Had To

The trial enrolled 80 adults with an average age of 54. To take part, their cholesterol had to be above common targets: a total cholesterol of at least 200 mg/dL, an LDL of at least 100 mg/dL, or both. Keep that detail in mind, because it means everyone started with cholesterol that was already worth watching.

Participants were randomly assigned to one of four groups for six to eight weeks. Everyone took capsules twice a day.

Because the trial was double-blind, neither the volunteers nor the people running it knew who was in which group. Because it was placebo-controlled, every result could be compared with people who followed exactly the same routine without the compound.

And it measured broadly. The researchers did not only look for the benefit they hoped to find. They tracked blood pressure, body weight and cholesterol, and they ran the standard blood tests of liver function, kidney function and blood sugar that doctors use to check that a substance is not causing harm.

That breadth is not a formality. A trial that measures only what it hopes to improve can only ever produce good news or no news. A trial that also measures what could go wrong can produce bad news, and that possibility is exactly what makes its good news worth something.

Section 2

The Good Number and the Awkward One

Start with the good number. In the high-dose group, taking 250 mg of pterostilbene a day, systolic blood pressure fell by 7.8 mmHg and diastolic blood pressure by 7.3 mmHg. Both changes were statistically significant.

Systolic is the top number in a reading such as 135/85, the pressure while the heart beats. Diastolic is the bottom number, the pressure between beats. A change of several points in a study lasting six to eight weeks is large enough for researchers to take notice, though one short trial is never where that story ends.

Now the awkward number. In the people taking pterostilbene on its own, LDL cholesterol, the fraction usually described as the one to keep in check, rose by an average of 17.1 mg/dL. That is about 0.44 mmol/L in the units used on most European lab reports, and the rise was also statistically significant.

Read that table slowly. The same compound, in the same kind of people, over the same weeks, moved one marker in a direction you would welcome and another in a direction you would not. The researchers did not drop the second line or bury it in an appendix. They put it in the abstract, the short summary at the top of the paper that most people read.

They also reported a pattern inside the LDL result. People who were already taking cholesterol-lowering medication showed less of the rise. That does not explain why the rise happened, but it is the kind of detail that only appears when researchers look closely at their own unwelcome finding rather than away from it.

Section 3

Why the Awkward Number Is the Reason to Trust the Good One

There is a simple reason an inconvenient result raises confidence. Every study involves choices: which outcomes to report, which groups to compare, which analyses to show. A team set on presenting a compound in the best possible light has plenty of room to do so, and readers rarely see what was left out.

When a paper reports a result that works against its own subject, you learn something about how those choices were made. This team was willing to show you a number that did not flatter pterostilbene. That makes it more likely that the numbers which do flatter it were reported the same way: as measured.

The same team also published a separate report devoted entirely to safety in this trial. Of the people who enrolled, 91.3% completed it. The liver, kidney and blood-sugar markers showed no adverse reactions, and there were no statistically significant differences in the side effects participants reported themselves.

The authors concluded that pterostilbene was generally safe for use in people at doses up to 250 mg a day. That conclusion has a boundary, and it is worth stating plainly: it covers the doses and the six-to-eight-week period this trial studied, not every dose or every length of use.

Put the two papers side by side and you have a fuller picture than many supplement studies give you: a benefit, an unwanted change in one blood marker, a clean result on the standard safety tests, and a clear statement of the dose range studied.

It also leaves an obvious question. If pterostilbene raised LDL on its own, why did the rise not appear in the group that took it with grape extract? To answer that properly, we first need to look at what pterostilbene is, and how it differs from the better-known molecule it is so often compared with.

Section 4

What This Trial Could Not Tell Us

A careful trial is still one trial, and it has edges. Knowing where they are is part of reading it well.

Who took part. Every volunteer started with cholesterol above common targets, the average age was 54, and about 71% were women. The results describe people like them. They do not tell us what happens in people with low cholesterol, in much older adults, or in men as reliably as in women.

How long it lasted. Six to eight weeks is long enough to see changes in blood pressure and blood fats. It is not long enough to know what happens after six months or six years of daily use.

How big it was. Eighty people split four ways leaves about twenty per group. That is enough to detect the larger changes, and too few to rule out smaller ones in either direction.

Which dose did what. The blood-pressure fall was reported for the 250 mg dose. It would be a mistake to assume that every dose, or every product containing pterostilbene, produces the same change.

None of this is a criticism of the researchers. These are the normal limits of a first, well-run human trial, and the paper is more useful for being read with them in view.

🔒 LOCKED: EXCLUSIVE READER REWARD

There is a private, unadvertised reader reward waiting at the end of this article.

Read the next two chapters closely. Score at least 4 out of 5 on the Final Master Quiz at the bottom of the page and we will unlock a reward chosen for the reader who has just understood this trial, together with a private code that never appears on our public pages. Valid 22 to 25 October 2026.

The answers are all in the chapters ahead…

[ Jump to the Final Master Quiz → ]

Chapter 2

Resveratrol’s Cousin With Two Small Changes

If you have spent any time reading about longevity compounds, you have met resveratrol. If you read our recent article on the lining that ages, you met it there too, in the polyphenol trials on blood-vessel function.

Pterostilbene is resveratrol’s chemical cousin. The two molecules share the same backbone: two ring structures joined by a short bridge, a shape chemists call a stilbene. That shared shape is why the two are so often discussed together.

The difference between them is small on paper. In the body, it appears to matter a great deal.

Section 1

Two Methyl Groups

Resveratrol carries three hydroxyl groups, small oxygen-and-hydrogen units, at fixed positions on its rings. Chemists write it as 3,5,4′-trihydroxy-trans-stilbene: three hydroxyls, at positions 3, 5 and 4′.

Pterostilbene keeps the hydroxyl at position 4′. At positions 3 and 5, each hydroxyl is capped with a methyl group, a single carbon atom with three hydrogens, which turns it into what chemists call a methoxy group. Its formal name is 3,5-dimethoxy-4′-hydroxy-trans-stilbene, and researchers often describe it simply as resveratrol’s dimethylether analogue.

Why might two caps matter? The usual explanation runs like this. Hydroxyl groups make a molecule more water-friendly, and they give the body convenient handles for attaching other molecules, one of the main ways it tags compounds for removal. Capping two of those handles makes pterostilbene more fat-friendly and leaves it fewer handles to be grabbed by.

That explanation is reasonable chemistry, but it is reasoning rather than a measured result. What has been measured is how much of each compound reaches the blood, and so far that has been measured in animals.

Section 2

What “More Bioavailable in Rats” Does and Doesn’t Mean

The number most often quoted about pterostilbene comes from a 2011 study in rats. Researchers gave the animals resveratrol or pterostilbene by mouth every day for 14 days, at doses matched molecule for molecule. They also gave both compounds directly into the bloodstream, so the two routes could be compared.

Bioavailability is the share of a dose taken by mouth that reaches the general circulation, compared with the same dose delivered straight into a vein. In these rats, oral bioavailability was about 80% for pterostilbene and about 20% for resveratrol.

That is a striking gap, and it is the origin of the claim, common online, that pterostilbene is “four times more bioavailable”. We do not use that phrase, for three reasons.

First, rats are not people. The way polyphenols are absorbed and processed differs between species, so a ratio measured in rats cannot simply be carried across to humans.

Second, the doses were large. The rats received 56 or 168 mg of pterostilbene per kilogram of body weight per day, matched by equivalent doses of resveratrol. Even after the standard adjustment for body size, that corresponds to roughly half a gram to two grams a day for an adult, well above the 100 to 250 mg a day used in the human trial.

Third, reaching the blood is only the first step. Bioavailability tells you how much arrives, not what it does when it gets there. Answering that second question is what the human trial in Chapter 1 was for.

So the fair summary is narrower than the slogan: in rats, at matched doses, much more pterostilbene than resveratrol reached the bloodstream. It is a good reason to study pterostilbene in people. It is not, by itself, a reason to expect any particular effect in you.

Section 3

A Molecule That Reaches the Blood May Behave Differently

This is where Chapter 1’s awkward number comes back in. If pterostilbene and resveratrol were interchangeable, you might expect them to behave the same way everywhere in the body. The difference in structure, and the difference in how much reaches the circulation in animals, are reminders that they are not.

Nobody has shown why pterostilbene on its own raised LDL in that trial. The paper reports the rise; it does not establish a mechanism, and we are not going to invent one. What we can say, as reasoning rather than evidence, is that a compound that gets into the blood more completely has more opportunity to have effects, wanted and unwanted, than one that is mostly cleared on the way in.

That is the honest frame for everything that follows. Pterostilbene is not “resveratrol, but better”. It is a related molecule with its own human data, including one result worth managing.

Section 4

Not Rivals, Not Replacements

It is tempting to turn all this into a contest: pterostilbene beats resveratrol because more of it reaches the blood. The evidence in this article does not support a contest.

The rat study compared absorption, not effects. The human trial in Chapter 1 tested pterostilbene against a placebo, not against resveratrol. To say that one is better than the other for any particular outcome, you would need a human trial comparing the two directly, and neither study here was designed to do that.

What the evidence does support is narrower and more useful. Pterostilbene is a separate compound with its own human trial, its own safety report and its own result to manage. If you take it, you should judge it on that evidence, not on resveratrol’s reputation, good or bad.

Chapter 3

The Arm Where the Rise Disappeared

Go back to the four groups in the trial. Three of them took pterostilbene. Two took it on its own, at different doses. One took it together with a grape extract: 50 mg of pterostilbene and 100 mg of grape extract, twice a day.

Researchers call each group in a trial an arm. This chapter is about that third arm, because it holds the result that matters most to anyone who takes pterostilbene.

Section 1

The Combination Arm

When the researchers compared LDL changes, the people taking pterostilbene alone showed the significant rise described in Chapter 1. In the combination arm, there was no statistically significant rise. The P value for that comparison was 0.47, far from the threshold that would suggest a real change.

That is the third result we promised at the start. It is also the result our own formula follows, which is exactly why we want to be careful with it.

Section 2

Three Reasons to Read It Carefully

A result you like deserves the same scrutiny as a result you don’t. Here are the three limits we would want a friend to know about before drawing any conclusion.

1. The pterostilbene dose was lower. The combination arm took 100 mg of pterostilbene a day, well below the 250 mg of the high-dose arm. A lower dose could explain part of the difference, and a trial of this size cannot fully separate the effect of the grape extract from the effect of the dose.

2. The groups were small and the trial was short. Eighty people divided four ways is about twenty per group, followed for six to eight weeks. “No significant rise” in about twenty people is not proof that no rise happens. It means the trial did not detect one.

3. “Grape extract” is a broad term. The extract used in the trial is not necessarily the same as the grape seed extract in any particular product, including ours. Extracts from different parts of the grape, made in different ways, contain different mixes of polyphenols.

None of these limits cancels the finding. Together they tell you how much weight it can carry: enough to make the pairing the more sensible way to take pterostilbene, not enough to promise that anyone’s LDL will stay exactly where it was.

Section 3

What This Means if You Take Pterostilbene

If you already take pterostilbene, or you are considering it, this is how we would use the trial.

Know your starting point. Every volunteer began with cholesterol above common targets. If you have had a recent lipid test, you already have a baseline. If you have not, your numbers are worth knowing, whatever you decide about supplements.

If you monitor your cholesterol or take medication for it, talk to your doctor first, and consider a repeat lipid test after two or three months. That is the simplest way to see how your own body responds, something no trial average can tell you.

Stay within the studied range. The trial and its safety report cover doses up to 250 mg of pterostilbene a day for six to eight weeks. Longer use and higher doses have less human evidence behind them.

Prefer the pairing to the compound on its own. On current evidence, pterostilbene taken with a grape extract is the version in which the LDL rise was not seen. It is one small trial, but it is the best human evidence there is on this question.

Section 4

Where This Leaves You

That last point is how we formulate our own pterostilbene. Pterostilbene Extreme + Grape Seed provides 200 mg of trans-pterostilbene with 200 mg of grape seed extract in a daily serving of two capsules.

The daily pterostilbene amount sits between the trial’s 100 mg and 250 mg doses. The grape component follows the combination arm, which took 200 mg of grape extract a day.

We want to be precise about what that does and does not mean. This exact combination, 200 mg plus 200 mg, has not itself been tested in a published trial, and grape seed extract is one particular kind of grape extract. What the formula does is follow the pairing used in the arm where LDL did not rise, at a pterostilbene dose inside the range the safety report covers.

If you decide to try it, the advice in Section 3 still applies: a baseline lipid test if you have one, a word with your doctor if cholesterol is something you already manage, and a recheck after a couple of months. That is how a careful trial becomes a careful personal decision.

Complete Reference List

The human trial

Structure and absorption (rats)